StockData

Garmin vs Northrop Grumman

GRMN and NOC side by side, both in measuring, analyzing, and controlling instruments; photographic, medical and optical goods; watches and clocks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GRMN and NOC compare

Northrop Grumman is the larger company, worth 1.4 times as much as Garmin ($78.2B against $54.5B).

On earnings, Northrop Grumman is cheaper: it trades at 17.4× trailing earnings, against 27.2× for Garmin.

Garmin grew revenue faster over the last twelve months (13.6% versus 6.5% for Northrop Grumman).

Garmin keeps more of each dollar of sales as profit, with a net margin of 25.6% compared with 10.4% at Northrop Grumman.

Both pay dividends: Garmin yields 1.4% and Northrop Grumman 1.7%.

Garmin scores higher on the StockData Score (22 against 18 for Northrop Grumman), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGRMNNOC
Size and price
Market cap$54.5B$78.2B
Share price$283.03$550.43
Change, 1 year42.5%−1.5%
Change, 5 years98.2%55.9%
Beta (5Y)0.960.31
Employees6,50095K
StockData Score
Total score22 (better)18
Valuation score13 (better)
Growth score6 (better)2
Performance score6 (better)5
Health score6 (better)4
Dividend score34 (better)
Valuation
P/E27.2×17.4× (better)
P/S6.9×1.8× (better)
P/B5.7×4.2× (better)
EV/EBITDA23.0×14.6× (better)
P/FCF37.2×20.4× (better)
PEG1.40–
FCF yield2.7%4.9% (better)
Fair value$255.38$625.70
Margin of safety−10.8%12.0% (better)
Growth
Revenue growth (TTM)13.6% (better)6.5%
Revenue growth, 5Y average11.6% (better)2.7%
Net income growth (TTM)28.4% (better)12.5%
EPS growth (TTM)28.5% (better)14.0%
EPS growth, 5Y average10.7% (better)8.9%
Profitability
Gross margin61.1%–
Operating margin28.8% (better)10.6%
Net margin25.6% (better)10.4%
FCF margin18.6% (better)8.8%
Return on equity22.4%26.1% (better)
Return on invested capital28.8% (better)13.3%
Financial health
Debt / equity0.000.81 (better)
Net debt / EBITDA–1.86
Current ratio3.05 (better)1.23
Altman Z-score16.00 (better)3.08
Piotroski F-score7 (better)6
Dividends and buybacks
Dividend yield1.4%1.7% (better)
Payout ratio37.2%30.2%
Years of dividend growth–16
Dividend growth, 5Y average–9.7%
Buyback yield–0.67%
Shareholder yield1.4%2.4% (better)
Ownership
Held by institutions57.1%83.5%
Held by insiders17.9%0.22%
Insider net buying, 12 months−$20.0M (better)−$26.4M
Superinvestors holding–1
Short interest, % of float2.0%1.5%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.